Recommendation 25: We recommend that high-sensitivity troponins be measured on admission for acute HF, to rule out acute coronary syndromes and for prognostic stratification (Strong Recommendation, High Quality Evidence).
Values and preferences: The degree of hs-troponin elevation is a powerful predictor of mortality and cardiovascular events in both ambulatory and acutely decompensated patients with chronic HFrEF, even after adjustment for traditional risk predictors including NPs. However, it is yet unclear how the use of serial hs-troponin measurements in addition to NPs for HFrEF management would provide additional and cost-effective benefits in terms of improving outcomes. Also, limited data are available regarding the prognostic significance of hs-troponin elevations in ambulatory patients with HFpEF.